Share：
Share this content in WeChat
X
[Chinese][PDF]112475
• Clinical Article •
Early evaluation of 131I nuclide therapeutic effect in Graves’ disease patients by MRI
WANG Zhong-wei  CHEN Jiao  LIU Bing  HAN Wei  ZHENG Wei  MENG Zhao-wei  ZHANG Gui-zhi  SUN Hao-ran 

DOI:10.3969/j.issn.1674-8034.2014.01.008.


[Abstract] Objective: To evaluate the early effect of 131I nuclide therapy in Graves’ disease by MRI.Materials and Methods: MRI was performed in 18 GD patients before and at 1, 3 months after 131I nuclide therapy respectively. According to the follow-up thyroid function laboratory results at 3 months, the enrolled GD patients were divided into effective group (n=9) and ineffective group (n=9). Overall thyroid volume and apparent diffusion coefficient (ADC) values were measured blindly and the changes of volumes and ADCs were compared longitudinally in both groups.Results: Compared with GD patients before 131I nuclide therapy, the thyroid volume decreased significantly in effective group (P<0.01) in the patients one month after therapy, while there was no change in ineffective group (P=0.07), and there was no change for the average thyroid ADC values in both groups (P=0.54, 0.27). The thyroid volume decreased significantly in both effective group (P<0.01) and ineffective group (P<0.05) in GD patients three months after therapy compared with patients before therapy; the average thyroid ADC values decreased in effective group (P<0.05), however, there was no change in ineffective group (P=0.46). The thyroid volume decreased significantly in effective group (P<0.05) but there was no change in ineffective group (P=0.20) three months after therapy compared with that of one month after therapy, and there was no change for the average thyroid ADC values in both groups (P=0.53, 0.08) between three and one months after therapy.Conclusion: The overall thyroid volume and the average ADC values could demonstrate early response after 131I nuclide therapy in Graves’ disease patients.
[Keywords] Graves’ disease；Diffusion magnetic resonance imaging；Iodine isotopes；Follow-up studies

WANG Zhong-wei Department of Radiology, Tianjin Medical University General Hospital, Tianjin 300052, China

CHEN Jiao Department of Radiology, Tianjin Medical University General Hospital, Tianjin 300052, China

LIU Bing Department of Radiology, Tianjin Medical University General Hospital, Tianjin 300052, China

HAN Wei Department of Radiology, Tianjin Medical University General Hospital, Tianjin 300052, China

ZHENG Wei Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China

MENG Zhao-wei Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China

ZHANG Gui-zhi Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China

SUN Hao-ran* Department of Radiology, Tianjin Medical University General Hospital, Tianjin 300052, China

*Correspondence to: Sun HR, E-mail: sunhaoran2006@hotmail.com

Conflicts of interest   None.

Received  2013-12-10
Accepted  2013-12-25
DOI: 10.3969/j.issn.1674-8034.2014.01.008
DOI:10.3969/j.issn.1674-8034.2014.01.008.

[1]
陆再英，钟南山，谢毅,等.内科学．7版．北京:人民卫生出版社,2008:712-722.
[2]
Tezuka M, Murata Y, Ishida R, et al. MR imaging of the thyroid: correlation between apparent diffusion coefficient and thyroid: gland scintigraphy. J Magn Reson Imaging, 2003, 17(2): 163-169.
[3]
Bozgeyik Z, Coskun S, Dagli AF, et al. Diffusion-weighted imaging of the thyroid nodules. Neuroradiology, 2009, 51(3): 193-198.
[4]
Erdem G, Erdem T, Muammer H, et al. Diffusion-weighted images differentiate benign from malignant thyroid nodules. J magn Reson imaging, 2010, 31(1): 94-100.
[5]
Mutlu H, Sivrioglu AK, Sonmez G, et al. Role of apparent diffusion coefficient values and diffusion-weighted magnetic resonance imaging in differentiation between benign and malignant thyroid nodules. Clin imaging, 2012, 36(1): 1-7.
[6]
靳勇，强金伟，冯琴,等.甲状腺结节的MR扩散加权成像与病理对照.中国医学影像技术, 2012, 28(2): 256-260.
[7]
Abdel Razek AA, Sadek AG, Gaballa G. Diffusion-weighted MR of the thyroid gland in Graves’ disease: assessment of disease activity and prediction of outcome. Acad Radiol, 2010, 17(6): 779-783.
[8]
陈娇，张桂芝，孟召伟,等. MR DWI在Graves病病情评估中的应用.中国医学影像技术, 2012, 28(11): 1977-1981.
[9]
岳秀慧，高欣，陶晓峰. MRI动态增强在甲状腺疾病诊断中的应用.磁共振成像杂志, 2012, 3(5): 361-366.
[10]
蔡冠虎.小剂量131碘治疗甲状腺功能亢进症近期疗效观察.中国热带医学, 2013, 13(8): 1018-1020.
[11]
周新建，李方，周前. Graves病131I治疗后重量和功能变化.中华内分泌代谢杂志, 2001, 17(4): 207-209.
[12]
黄智慧，谢彦，罗芙蓉,等. Graves病131I首次治疗的疗效与甲状腺大小的相关性分析.皖南医学院学报, 2011, 30(6): 461-463.

PREV The value of quantitative dynamic-enhanced MRI in evaluating extra-ocular muscle involvement in patients with chronic thyroid-associated ophthalmopathy
NEXT Preliminary study on pathomechanism of non-small-cell lung carcinoma using apparent diffusion coefficient
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn